News
SCNLD
0.141
NaN%
--
Scancell clears share consolidation as it readies AIM trading and deal push
TipRanks · 2d ago
Scancell Issues Shares Ahead of Consolidation and Publishes 2026 Annual Report
TipRanks · 10/15 06:08
Scancell Bolsters Cancer Immunotherapy Push With Nasdaq Move and $75m Funding
TipRanks · 10/09 06:11
Scancell Secures Up to US$25m BlackRock Debt to Drive iSCIB1+ Phase 3
TipRanks · 09/24 06:15
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
Barchart · 09/24 00:00
Scancell to Highlight Late-Stage Cancer Immunotherapy and U.S. Deal Plans at Wainwright Conference
TipRanks · 09/03 13:03
Scancell Wins UK Green Light for Global Phase 3 Melanoma Trial of iSCIB1+
TipRanks · 08/19 06:09
Scancell Extends CSO Share Option Exercise Period
TipRanks · 07/31 06:08
Scancell Raises £15.7m After Oversubscribed Retail Offer and UK Placing
TipRanks · 07/27 06:08
Scancell and Neuphoria in all-share merger backed by $89m financing for melanoma trial
TipRanks · 07/24 06:32
Scancell upsizes oversubscribed £13m UK placing to extend funding runway
TipRanks · 07/23 15:32
Scancell launches discounted UK share placing to fund Phase 3 melanoma trial
TipRanks · 07/23 07:08
Scancell launches retail offer and placing to extend cash runway into 2027
TipRanks · 07/23 07:07
Scancell to Merge with Neuphoria and Secure Up to $89m for Phase 3 Melanoma Trial
TipRanks · 07/23 07:07
Scancell in advanced talks on Neuphoria reverse merger and Nasdaq listing
TipRanks · 06/26 13:17
Scancell Wins FDA Fast Track for Melanoma Vaccine as Phase 2 Data Strengthen
TipRanks · 04/28 06:09
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
Barchart · 04/28 01:00
Scancell Taps Veteran Biotech Financier as Interim CFO Amid iSCIB1+ Push
TipRanks · 04/02 06:16
Scancell Holdings Charts Risky but Promising Phase III Path
TipRanks · 01/31 00:23
Scancell Holdings plc GAAP EPS of -£0.64p
Seeking Alpha · 01/29 15:31
More
Webull provides a variety of real-time SCNLD stock news. You can receive the latest news about Scancell Holdings Plc London through multiple platforms. This information may help you make smarter investment decisions.
About SCNLD
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.